MSD & Kyowa Question NICE’s Processes After English Funding Rejected For Rare Disease Drugs
MSD and Kyowa Kirin have separately criticized England’s HTA body, NICE, for assessing their respective rare disease medicines Welireg and Crysvita using its standard appraisal pathway. Both medicines were provisionally rejected for reimbursement.
You may also be interested in...
The EU must adopt a more comprehensive policy on rare diseases to increase the number of orphan drugs and address access challenges, says EURORDIS’ chief executive Yann Le Cam.
Alexion has secured funding for its Wolman disease drug Kanuma via England’s Innovative Medicines Fund after several years of “constructive collaboration” with the country’s health technology assessment body NICE and the National Health Service.
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.